Norway, 11 November 2021 - ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, has today announced the launch of MYRELEZ® (lanreotide) in Norway, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumours and symptoms associated with neuroendocrine tumours.[i]*
Acromegaly is a rare disease caused by excessive Growth Hormone (GH) secretion. It is usually diagnosed in adults aged 30 to 50, although can affect people at any age, and is characterised by allowing bones and tissue to grow more quickly, as well as a wide range of other symptoms.[ii] Neuroendocrine tumours (NETs) are rare tumours that can appear anywhere in the neuroendocrine system, the system that controls hormones.[iii] When a NET is in the gastroenteropancreatic (GEP) system (digestive tract or pancreas) it is known as a GEP-NET.[iv]
David Johnson, Global Director, Commercial Excellence, ADVANZ PHARMA said: “Until now, prescriber choice has been limited. The launch of a generic alternative means we are able to improve access and choice while helping to drive down costs.”
Paul Burden, Chief Commercial Officer, Strategic Business Unit, said: “At ADVANZ PHARMA, we have a deep-rooted and specialist knowledge in the off-patent and complex medicine space, enabling us to create a wider choice of more affordable products. This provides hospitals and healthcare professionals with the opportunity to free up budget to spend elsewhere, delivering value and benefit to patients, healthcare providers and healthcare systems as a whole.
“It is through our successful partnerships with regulators, manufacturers and distributors across the region that today’s news has been made possible. We’re proud to announce the launch of this medicine in the Nordics today and look forward to expanding this to other countries across Europe in the near future.
“This launch is the first of what we hope will be many, as we continue to expand into the complex and value-added medicines space, to the benefit of healthcare professionals and patients in Europe.”
Notes to editors
About MYRELEZ® (lanreotide) *Lanreotide is indicated for:1
- The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment.
- The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
- The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.
About ADVANZ PHARMA
ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines in Europe. With an agile and experienced team, including direct sales, marketing and medical capability across many of Europe’s major markets, the Company supplies, innovates and enhances the critical medicines patients depend on, ensuring continued patient access and improving health outcomes.
With its European network and its expertise in the anti-infectives and endocrinology therapy areas, ADVANZ PHARMA is an attractive partner when commercialising complex medicines in Europe.
ADVANZ PHARMA has an operational headquarters in London, an operations centre of excellence in Mumbai, commercial affiliates in North America, Europe, and Australia, and an established global network of commercial partners throughout the rest of the world.
For more information please visit: https://www.advanzpharma.com/
[i] MYRELEZ (lanreotide) Summary of Product Characteristics. Updated December 2019
[ii] NHS. Acromegaly. Available at: https://www.nhs.uk/conditions/acromegaly/. Last accessed June 2021
[iii] Neuroendocrine tumor. Genetic and Rare Disease Information Center. NIH. https://rarediseases.info.nih.gov/diseases/13445/neuroendocrine-tumor . Last accessed: November 2021
[iv] Everyday Health. What Are Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). Available at: https://www.everydayhealth.com/gastroenteropancreatic-neuroendocrine-tumors-gep-nets/. Last accessed June 2021